New HIV drugs in development, 2005

Current Infectious Disease Reports

Volumn 7, Issue 3, 2005, Pages 221-226

  Nadler, Jeffrey P ^a   Phillips, Michael C ^b  

^a TAMPA GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APLAVIROC; CAPRAVIRINE; CHEMOKINE RECEPTOR CCR5; CYTIDINE DERIVATIVE; DARUNAVIR; EFAVIRENZ; ELVUCITABINE; ENFUVIRTIDE; ETRAVIRINE; GLYCOPROTEIN GP 120; INTEGRASE INHIBITOR; L 870; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPD 754; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BONE MARROW DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATTY LIVER; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IC 50; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; LONG TERM CARE; MYOPATHY; MYOSITIS; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RETROVIRUS; REVIEW; TREATMENT PLANNING; VIRUS RESISTANCE;

EID: 19144365154     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0038-5     Document Type: Review

References (46)

1. Furman PA, Barry DW. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med 1988, 85:176-181.
2. Goody RS, Muller B, Restle T: Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett 1991, 291:1-5.
3. Squires KE: An introduction to nucleoside and nucleotide analogues. Antivir Ther 2001, 6(Suppl 3):1-14.
4. Nolan D, Mallal S: Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004, 9:849-863.
5. Gotte M, Wainberg MA: Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updat 2000, 3:30-38.
6. Murphy RL, Schürmann D, Beard A: Potent anti-HIV-1 activity of Reverset (TM) following 10 days of monotherapy in treatment-naïve individuals. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:1-26.
7. Bethell RC, De Rooj ER, Smolders KGM, et al.: Comparison of the in vitro mitochondrial toxicity of SPD754 in HepG2 cells with nine other nucleoside reverse transcriptase inhibitors. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004:H-207-2004.
8. Adams J: Intracellular SPD754 triphosphate pharmacokinetics following administration of SPD754 capsules [abstract 599]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
9. Holdich T, Shiveley LA, Sawyer J: Phase I study investigating the plasma and intracellular pharmacokinetics of SPD754 and 3TC when administered alone and in combination. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:1-373.
10. R Bethell, Adams J, De Muys J, et al.: Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [abstract 138]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
11. Bethell R, Collins P, de Muys J, et al.: An in vitro evaluation of the intracellular anabolism of SPD754 and FTC alone and in combination. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:1-372.
12. Andries K, Azijn H, Thielemans T, et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:4680-4686.
13. Vingerhoets J, De Baere I, Azijn H, et al.: Antiviral activity of TMC125 against a panel of site-directed mutants encompassing mutations observed in vitro and in vivo [abstract 621]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
14. Lazzarin A, Arribas J, Pozniak A, et al.: Sustained antiviral activity of TMC125 plus optimized ART in highly treatment experienced patients [poster 316]. Poster presented at the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 14-18, 2004.
15. Gewurz BE, Jacobs M, Proper JA, et al.: Capravirine, a nonnucleoside reverse transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis 2004, 190:1957-1961.
16. Diniz-Piraino S, Hawley P, Paxton W, et al.: Assessment of patients on capravirine for vasculitis: a clinical and epidemiologic study [abstract C11051]. Paper presented at the 14th International AIDS Conference. Barcelona, Spain, July 7-12, 2002.
17. Flexner C: HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1293.
18. Miller KD, Jones E, Yanovski JA, et al.: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
19. Lo JC, Mulligan K, Tai VW, et al.: "Buffalo hump" in men with HIV-1 infection. Lancet 1998, 351:867-870.
20. Ben-Romano R, Rudich A, Torok D, et al.: Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003, 17:23-32.
21. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. AIDS 1998, 12:F51-F58.
22. Carr A, Samaras K, Thorisdottir A, et al.: Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
23. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
24. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997, 277:145-153.
25. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
26. Larder BA, Hertogs & Bloor S, et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14:1943-1948.
27. Yeni P: Tipranavir: a protease inhibitor from a new class with distinct antiviral activity [optimising HIV treatment--building on experience; based on a symposium held Friday 15 March 2002, Seville, Spain]. J Acquir Immune Defic Syndr 2003, 34:S91-S94.
28. Yeni P, MacGregor T, Gathe J: Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir (TPV/RTV) in a phase IIb trial [abstract 528]. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Foundation for Retrovirology and Human Health; 2003.
29. Hicks C: RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2004:H-1137a.
30. Taton V, Curt M: An open-label expanded access program (EAP) to assess the safety of tipranavir co-administered with low-dose ritonavir (TPV/r) in patients with advanced HIV-1 infection and limited treatment options. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:2-366.
31. De Meyer S, Van Marck H, Van den Bulcke T, et al.: Phenotypic and genotypic profiling of TMC114, a potent next generation PI against > 2000 recent PI-resistant clinical isolate [poster 3.11]. Poster presented at the Second European HIV Drug Resistance Workshop. Rome, Italy, March 11-13, 2004.
32. De Meyer S, Van Marck H, Van Den Bulcke T, et al.: Phenotypic and genotypic profiling of TMC114, a potent next-generation PI, against some 1600 recent PI-resistant clinical isolates [abstract 620]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
33. Peeters M, Van Baelen B, De Meyer S, et al.: TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14 [abstract 533]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
34. Nicholson JK, Browning SW, Hengel RL, et al.: CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:105-115.
35. Feng Y, Broder CC, Kennedy PE, et al.: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-876.
36. van der Ryst E, Rosario MC, Poland W, et al.: Modelling of UK-427,857, a novel CCR5 antagonist, efficacy in short-term monotherapy. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:1-341.
37. Mansfield RW, Napier CM, Sale HE, et al.: UK-472,857 binding characteristics to human and animal recombinant CCR5 receptors. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:2-15.
38. van der Ryst E, Rosario MC, Poland W, et al.: Evaluation of dosing frequency and food effect on viral load reduction during short term monotherapy with UK-427,857, a novel CCR5 antagonist. Proceedings of the XV International AIDS Conference. Bangkok, Thailand: International AIDS Society; 2004:1-343.
39. van der Ryst E, Westby M, James I, et al.: Reversible predominance of CXCR4 utilising variants in a non-responsive dual tropic patient receiving the CCR5 antagonist UK-427,857 [abstract 538]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
40. Lalezeri J, Thompson M, Kumar P, et al.: 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2004:H-1137b-2004.
41. Demarest J, Adkison K, Sparks S, et al.: Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects [abstract 139]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
42. Hanna G, Yan JH, Fiske W, et al.: Safety, tolerability, and pharmacokinetics of a novel, small-molecule HIV-1 attachment inhibitor, BMS-488043, after single and multiple oral doses in healthy subjects [abstract 535]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
43. Hanna G, Masterson T, Lalezari J, et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects [abstract 141]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
44. Lin PF, Ho HT, Gong YF, et al.: Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action [abstract 534]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
45. Fikkert V, Hombrouck A, Van Remoortel B, et al.: Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004, 18:2019-2028.
46. Fikkert V, Van Maele B, Vercammen J, et al.: Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003, 77:11459-11470.